SCHEMBL26097052

SCHEMBL26097052

Cc1ccc(CNC(=O)c2cc(Cl)ccc2O)cc1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 4/20 0.63
TUBB P07437 2/20 0.62
P2RX1 P51575 2/20 0.62
TMPRSS4 Q9NRS4 2/20 0.62
MEN1 O00255 2/20 0.58
KMT2A Q03164 2/20 0.58
KDM4E B2RXH2 2/20 0.58
LMNA P02545 1/20 0.58
PLA2G1B P04054 1/20 0.58
MAPT P10636 1/20 0.58
XBP1 P17861 1/20 0.58
ALOX12 P18054 1/20 0.58
HTT P42858 1/20 0.58
KCNH2 Q12809 1/20 0.58
ATG4B Q9Y4P1 1/20 0.58
CDK1 P06493 1/20 0.56
POLA1 P09884 2/20 0.55
CA1 P00915 1/20 0.55
CA2 P00918 1/20 0.55
NPC1 O15118 2/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23675446 0.91 TUBB (0.72) HPGDTUBBP2RX1TMPRSS4MEN1
SCHEMBL13812916 0.89 P2RX1 (0.66) HPGDTUBBP2RX1TMPRSS4MEN1
SCHEMBL13812639 0.86 P2RX1 (0.66) TUBBP2RX1TMPRSS4MEN1KMT2A
SCHEMBL30100461 0.85 TUBB (0.75) HPGDTUBBP2RX1TMPRSS4MEN1
SCHEMBL13236587 0.85 TUBB (0.75) HPGDTUBBP2RX1TMPRSS4MEN1
SCHEMBL4019571 0.84 TUBB (0.63) HPGDTUBBP2RX1TMPRSS4LMNA
SCHEMBL13812818 0.83 TUBB (0.69) HPGDTUBBP2RX1TMPRSS4MEN1
SCHEMBL11516368 0.83 LMNA (0.68) HPGDLMNAMAPTALDH1A1TP53
SCHEMBL30474376 0.83 HSP90AA1 (0.74) HPGDMEN1KMT2AKDM4EMAPT
SCHEMBL29200003 0.83 HSP90AA1 (0.74) HPGDMEN1KMT2AKDM4EMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230140290-A1 SALICYLAMIDE DERIVATIVES AND RELATED METHODS OF MAKING THE BOARD OF REGENTS OF THE UNIV OF TEXAS SY (US) 2023-05-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230140290-A1 SALICYLAMIDE DERIVATIVES AND RELATED METHODS OF MAKING EIF2AK2, SARS1, ACE HPGD 1066/4885TUBB 3158/4885P2RX1 3088/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.